Vanguard Fiduciary Trust
PMCB icon

Vanguard Fiduciary Trust’s PharmaCyte Biotech PMCB Stock Holding History

Vanguard Fiduciary Trust’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.1K Hold
23,452
– – ﹤0.01% 4007
2026
Q1 		$15.6K Buy
+23,452
New +$17.9K ﹤0.01% 3973

Other funds holding PMCB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Vanguard Fiduciary Trust's PMCB Position: Q2 2026 in Review

Vanguard Fiduciary Trust held its PharmaCyte Biotech (PMCB) position steady in Q2 2026 at 23,452 shares worth $18.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4007.

Vanguard Fiduciary Trust first reported a position in PMCB in Q1 2026 and has held it in 2 quarters since. 28 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

  • Vanguard Fiduciary Trust held 23,452 shares of PharmaCyte Biotech worth $18.1K as of Q2 2026.
  • Vanguard Fiduciary Trust left its PharmaCyte Biotech share count unchanged in Q2 2026.
  • PharmaCyte Biotech made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #4007 holding.
  • Vanguard Fiduciary Trust first reported a position in PharmaCyte Biotech in Q1 2026 and has held it in 2 quarters since.
  • 28 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.